At hearing, Makary nods to MAHA’s goals but says little about basic FDA policies

Taking stock of the drug industry, from the lab to the medicine chest

March 6, 2025 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Kayla Bartkowski/Getty Images STAT+ | At hearing, Makary nods to MAHA's goals but says little about basic FDA policies Trump's FDA nominee promises transparency and a focus on chronic disease, but is less forthright on medication abortion and advisory committees. By Lizzy Lawrence STAT+ | The numbers that tell a scary story about the state of biotech In this week's edition of "Adam's Biotech Scorecard," we take a closer look at small-cap biotechs, which are down 17%, on average, over three months. By Adam Feuerstein STAT+ | New radiopharmaceutical heading to the FDA after Phase 3 win The drug from ITM Isotope Technologies Munich SE has been developed as a treatment for gastroenteropancreatic neuroendocrine tumors. By Allison DeAngelis Adobe STAT+ | Trump's early actions imperil efforts to improve AI's performance in medicine Health secretary RFK Jr. wants AI to improve rural health but Trump's actions disrupt research critical to ensure the technology doesn't discriminate. By Katie Palmer

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2025, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser